Notably, IGFBP-6 levels are also sensitive to NAFLD treatments like tesamorelin, which prevents fibrosis progression, thus confirming its clinical relevance as a biomarker [120]. Here, IGFBP6 is linked to metabolic dysfunction-associated steatotic liver disease.